Antimicrobial therapy of community-acquired pneumonia

被引:24
作者
File, TM
Niederman, MS
机构
[1] Summa Hlth Syst, Akron, OH 44304 USA
[2] Northeastern Ohio Univ Coll Med & Pharm, Coll Med, Rootstown, OH 44272 USA
[3] Winthrop Univ Hosp, Mineola, NY 11501 USA
[4] SUNY Stony Brook, Stony Brook, NY 11794 USA
关键词
D O I
10.1016/j.idc.2004.07.011
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Community-acquired pneumonia (CAP) is a common disorder that is potentially life-threatening, especially in older adults and patients with comorbid disease. Despite substantial progress in therapeutic options, CAP remains a primary cause of death from infectious disease in the United States. The mainstay of treatment for most patients is appropriate antimicrobial therapy. This article reviews the principles for initial antimicrobial therapy, highlights some of the differences in approaches to antimicrobial drug selection in selected guidelines, and includes new recommendations for empiric and pathogen-directed therapy of CAP.
引用
收藏
页码:993 / +
页数:25
相关论文
共 77 条
[1]   Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia [J].
Anderson, KB ;
Tan, JS ;
File, TM ;
DiPersio, JR ;
Willey, BM ;
Low, DE .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (03) :376-381
[2]   Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa -: Incidence, risk, and prognosis [J].
Arancibia, F ;
Bauer, TT ;
Ewig, S ;
Mensa, J ;
Gonzalez, J ;
Niederman, MS ;
Torres, A .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (16) :1849-1858
[3]   Community-acquired pneumonia - A prospective outpatient study [J].
Bochud, PY ;
Moser, F ;
Erard, P ;
Verdon, F ;
Studer, JP ;
Villard, G ;
Cosendai, A ;
Cotting, M ;
Heim, F ;
Tissot, J ;
Strub, Y ;
Pazeller, M ;
Saghafi, L ;
Wenger, A ;
Germann, D ;
Matter, L ;
Bille, J ;
Pfister, L ;
Francioli, P .
MEDICINE, 2001, 80 (02) :75-87
[4]  
*BRIT THOR SOC, 2001, THORAX S4, V56
[5]   Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia - Analysis of a hospital claims-made database [J].
Brown, RB ;
Iannini, P ;
Gross, P ;
Kunkel, M .
CHEST, 2003, 123 (05) :1503-1511
[6]  
Campbell GD, 1998, CLIN INFECT DIS, V26, P1188, DOI 10.1086/520286
[7]   Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults - A randomized trial [J].
Chastre, J ;
Wolff, M ;
Fagon, JY ;
Chevret, S ;
Thomas, F ;
Wermert, D ;
Clementi, E ;
Gonzalez, J ;
Jusserand, D ;
Asfar, P ;
Perrin, D ;
Fieux, F ;
Aubas, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (19) :2588-2598
[8]   Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: A multicenter study [J].
ClavoSanchez, AJ ;
GironGonzalez, JA ;
LopezPrieto, D ;
CanuetoQuintero, J ;
SanchezPorto, A ;
VergaraCampos, A ;
MarinCasanova, P ;
CordobaDona, JA .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (06) :1052-1059
[9]   Brief report: Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. [J].
Davidson, R ;
Cavalcanti, R ;
Brunton, JL ;
Bast, DJ ;
de Azavedo, JCS ;
Kibsey, P ;
Fleming, C ;
Low, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (10) :747-750
[10]   Viral community-acquired pneumonia in nonimmunocompromised adults [J].
de Roux, AD ;
Marco, MA ;
Garcia, E ;
Mensa, J ;
Ewig, S ;
Lode, H ;
Torres, A .
CHEST, 2004, 125 (04) :1343-1351